Cipla Launches Ciposcillo Oscillometer for Early Respiratory Diagnostics in COPD and Asthma

Cipla's entry into next-generation respiratory diagnostics with the Ciposcillo oscillometer signals a broadening of the company's device portfolio beyond its established inhaled-therapy franchise, with direct implications for clinical procurement leads and respiratory care program managers evaluating point-of-care lung function tools.

The device is designed for early and accurate diagnosis of obstructive airway diseases, specifically COPD and asthma. Oscillometry measures respiratory mechanics by superimposing small pressure oscillations onto tidal breathing, requiring no forced maneuver from the patient — a meaningful clinical advantage over conventional spirometry in populations where effort-dependent testing yields inconsistent results.

Cipla has not disclosed the technical specifications, pricing tiers, or target care settings for Ciposcillo, leaving procurement teams with limited data to benchmark the device against established oscillometry platforms currently available in the Indian and export markets. Regulatory clearance details and the applicable conformity pathway have also not been confirmed in available disclosures.

For QA and regulatory leads tracking Cipla's device strategy, the launch extends the company's footprint into Class II medical device territory under India's Medical Devices Rules, 2017, a regulatory environment that has seen tightened post-market surveillance requirements since the 2023 amendment cycle. How Cipla structures its device quality management system relative to its pharmaceutical GMP infrastructure will be a practical question for any institution conducting supplier qualification audits.

The commercial trajectory of Ciposcillo will depend in part on how Cipla positions it within its existing respiratory sales network and whether the device is paired with its inhaler portfolio as a bundled diagnostic-and-therapy offering.

Source: Media4Growth via Indian Pharma Post, 5 May 2026.